Plasminogen Activator Inhibitor-1 （PAI-1, Serpin E1） is a member of the serpin family of serine protease inhibitors, and is the primary inhibitor of urokinase and tissue plasminogen activator （tPA）.
PAI-1 is expressed predominantly in adipose, liver and vascular tissues, but is also produced by certain tumor cells.
Elevated levels of PAI-1 are associated with obesity, diabetes and cardiovascular disease, and increased production of PAI-1 is induced by various obesity-related factors, such as TNFα, glucose, insulin, and very-low-density lipoprotein.
The obesity-related elevation of PAI-1 levels, along with the consequential deficiency in plasminogen activators, can lead directly to increased risk of thrombosis and other coronary diseases.
Accordingly, PAI-1 has been implicated as an important molecular link between obesity and coronary disease.
PAI-1 can also specifically bind vitronectin （VTN） to form a stable active complex with an increased circulatory half-life relative to free PAI-1.
The BioGems Human PAI-1 Pre-Coated ELISA （Enzyme-Linked Immunosorbent Assay） kit is a solid phase immunoassay specially designed to measure PAI-1 with a 96-well strip plate that is pre-coated with mouse monoclonal antibody specific for PAI-1.
It contains sf21-expressed recombinant PAI-1.
The detection antibody is a biotinylated goat polyclonal antibody specific for PAI-1.
The kit is analytically validated with ready to use reagents.
